drugset / Trial / NCT06211023

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

NCT06211023

Phase 2/3 Unknown 520 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.

Timeline

Start
2024-02-15
Primary completion
2026-06-15
Completion
2026-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 4 unknown
Subject Carboplatin Small molecule 5 unknown
Subject SHR-1921 Unknown

Indications